This comprehensive review synthesizes current knowledge across the full spectrum of AD, encompassing molecular pathophysiology (amyloid cascade, tau hyperphosphorylation, and neuroinflammation), genetic architecture, genetic architecture (familial mutations and APOE-mediated risk), evolving biomarker-based diagnostic frameworks, established symptomatic treatments, and newly approved disease-modifying agents.
Abstract Alzheimer’s disease (AD) usually follows a slowly progressive course, but some patients experience unusually rapid cognitive and functional decline. This clinical phenotype, commonly termed rapidly progressive Alzheimer’s disease (rpAD), has no consensus definition; its status as a distinct biological entity r...
Mei-Ling Cao, Lu-Ming Leng, Ping Liu et al.· Clinical Interventions in Ag...· 0 citations
Alzheimer’s disease (AD) is a devastating neurodegenerative disorder that affects millions of people worldwide and poses a major global health challenge. This complex disease involves multiple pathogenic factors, including amyloid-beta (Aβ), tau protein aggregation, synaptic dysfunction, mitochondrial impairment, oxida...
Mona Piplani, Shivani Thakur, Pankaj Kumar et al.· Biomedical & Pharmacolog...· 0 citations
Background: Alzheimer's disease is characterized by progressive cognitive decline and the accumulation of beta-amyloid and neurofibrillary tangles in the brain. Traditionally, treatments have only been symptomatic, but anti-amyloid monoclonal antibodies, such as lecanemab and donanemab, are emerging as therapies capabl...
Alzheimer's disease (AD) is a progressive neurodegenerative disorder and the leading cause of dementia worldwide accounting for an estimated 60% to 80% of cases. Biomarkers play an integral role in AD randomized clinical trials (RCTs), providing objective measures of disease pathology, progression, and therapeutic effi...
Xiao-Lan Zhang, Michael F. Murphy, Henry J. Riordan et al.· Bioanalysis· 0 citations
Alzheimer’s disease (AD) is one of the leading neurodegenerative disorders affecting over 55 million
individuals worldwide, with a limited selection of disease-modifying therapies. The amyloid cascade
hypothesis proposes that amyloid-beta (Aβ) peptide accumulation initiates a cascade of synaptic
dysfunction, neuroinfla...
R. Menon· American Journal of Student...· 0 citations
Alzheimer’s disease remains a major global health challenge, with limited disease-modifying therapies and a rapidly growing societal burden. Although amyloid and tau remain central to the field, current evidence also implicates neuroinflammation, immune dysregulation, vascular dysfunction, and host-microbe interactions...
J. A. Rice, Jean-Marie C. Bouteiller, A. Khachaturian· Frontiers in Molecular Medic...· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.